Post-transplant lymphoproliferative disorder in renal allograft recipients: Clinical experience and risk factor analysis in a single center

Transplantation

Volumn 56, Issue 1, 1993, Pages 88-96

  Cockfield, Sandra M ^a   Preiksaitis, Jutta K ^a   Jewell, Laurence D ^a   Parfrey, Nollaig A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CELL NUCLEUS ANTIGEN; CYCLOSPORIN; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; OKT 3; PREDNISONE; VIRUS CAPSID ANTIGEN;

ADULT; ARTICLE; CADAVER KIDNEY; EPSTEIN BARR VIRUS; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LYMPHOID HYPERPLASIA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANTILYMPHOCYTE SERUM; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; METHYLPREDNISOLONE; MIDDLE AGE; MUROMONAB-CD3; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T;

EID: 0027219310     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199307000-00016     Document Type: Article

References (40)

1. Purtilo DT. Epstein-Barr-virus-induced oncogenesis in immune-deficient individuals. Lancet 1980; 1: 300.
2. Cohen JI. Epstein-Barr virus lymphoproliférative disease associated with acquired immunodeficiency. Medicine 1991; 70: 137.
3. Stephanian E, Gruber SA, Dunn DL, Matas AJ. Posttransplant lymphoproliférative disorders. Transplant Rev 1991; 5; 120.
4. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of post-transplant lymphoproliférative disorders. Curr Prob Surg 1988; 25; 371.
5. Purtilo DT, Strom S, Okano M, Davis JR. Epstein-Barr virus-associated lymphoproliférative disorders. Lab Invest 1992; 67: 5.
6. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliférative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173.
7. Yousem SA, Randhawa P, Locker J, et al. Posttransplant lymphoproliférative disorders in heart-lung transplant recipients: primary presentation in the allograft. Hum Pathol 1989; 20: 361.
8. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23: 1101.
9. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262.
10. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency, and B cell lymphoprolifération. Transplantation 1985; 39: 461.
11. Cleary ML, Warnke R, Sklar J. Monoclonality of lymphoproliférative lesions in cardiac-transplant recipients. Clonal analysis based on immunoglobulin-gene rearrangements. N Engl J Med 1984; 310: 477.
12. Caine RY, Rolles S, Thiru S, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2: 1033.
13. Wilkinson AH, Smith JL, Hunsicker LG, et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989; 47:293.
14. Cockfield SM, Preiksaitis J, Harvey E, et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant post-transplant lymphoproliférative disorder? Transplant Proc 1991; 23: 1106.
15. Swinnen LG, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliférative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723.
16. Starzl TE, Porter KA, Iwatsuki S, et al. Reversibility of lymphomas and lymphoproliférative lesions developing under cyclosporine-steroid therapy. Lancet 1984; 1: 583.
17. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982; 306: 913.
18. Pirsch JD, Stratta RJ, Sollinger HW, et al. Treatment of severe Epstein-Barr virus-induced lymphoproliférative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med 1989; 86: 241.
19. Shapiro RS, Chauvenet A, McGuire W, et al. Treatment of B-cell lymphoproliférative disorders with interferon-alpha and intravenous gamma globulin. N Engl J Med 1988; 2: 1334.
20. Diaz-Mitoma F, Ruiz A, Flowerdew G, et al. High levels of Epstein-Barr virus in the oropharynx: a predictor of disease progression in human immunodeficiency virus infection. J Mol Biol 1990; 31: 69.
21. Denning DW, Weiss LM, Martinez K, Flechner SM. Transmission of Epstein-Barr virus by a transplanted kidney, with activation by OKT3 antibody. Transplantation 1989; 48:141.
22. Preiksaitis J, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrel DLJ. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serological responses and the risk of posttransplant lymphoproliférative disorder. J Infect Dis 1992; 166: 986.
23. Ho M, Miller G, Atchison RW. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliférative lesions: the role of primary infection. J Infect Dis 1985; 152: 876.
24. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliférative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719.
25. Thorley-Lawson DA. Basic virological aspects of Epstein-Barr virus infection. Semin Hematol 1988; 25: 247.
26. Bird AG, McLachlan SM, Britton S. Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature 1981; 289: 300.
27. Tsoukas CD, Carson DA, Fong S, Vaughan JH. Molecular interactions in human T cell-mediated cytotoxicity to EBV. II. Monoclonal antibody OKT3 inhibits a post-killer-target recognition/ adhesion step. J Immunol 1982; 129:1421.
28. Ren EC, Chan SH. Possible enhancement of Epstein-Barr virus infections by the use of OKT3 in transplant recipients. Transplantation 1988; 45: 988.
29. Thomas JA, Hotchin NA, Allday MJ, et al. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 1990; 49:944.
30. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliférative disease. N Engl J Med 1989; 321:1080.
31. Patton DF, Wilkowski CW, Hanson CA, et al. Epstein-Barr virus-determined clonality in posttransplant lymphoproliférative disease. Transplantation 1990; 49: 1080.
32. Katz BZ, Raab-Traub N, Miller G. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliférative diseases. J Infect Dis 1989; 160: 589.
33. Gamier JL, Berger F, Betuel H, et al. Epstein-Barr virus associated lymphoproliférative diseases (B cell lymphoma) after transplantation. Nephrol Dial Transplant 1989; 4: 818.
34. Markin RS, Wood RP, Shaw BW Jr, Brichacek B, Purtilo DT. Immunohistologic identification of Epstein-Barr virus-induced hepatitis reactivation after OKT-3 therapy following orthotopic liver transplant. Am J Gastroenterol 1990; 85: 1014.
35. Cen H, Breinig MC, Atchison RW, Ho M, McKnight JLC. Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4. J Virol 1991; 65: 976.
36. Tosato G, Tanner J, Jones KD, Revel M, Pike SE. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol 1990; 64: 3033.
37. O’Garra A, Stapleton G, Dhar V, et al. Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol 1990; 2: 821.
38. Eklund B, von Willebrand E, Hockerstedt K, et al. Lymphoproliférative disease after renal transplantation. Transplant Proc 1986; 18: 95.
39. Iwatsuki S, Geis WP, Molnar Z, Giacchino JL, Ing TS, Hano JE. Systemic lymphoblastic response to antithymocyte globulin in renal allograft recipients: an initial report. J Surg Res 1978; 24: 428.
40. Hanto DW, Birkenbach M, Frizzera G, Gajl-Peczalska KJ, Simmons RL, Schubach WH. Confirmation of the heterogeneity of posttransplant Epstein-Barr virus-associated B cell proliferations by immunoglobulin gene rearrangement analyses. Transplantation 1989; 47: 458.